HEALTHCARE

Arkin Digital Health is being rebranded as A-Squared Ventures, as it brings in more outside investors and operates more independently.

Despite concerns, the forecast for sales of branded drug Austedo remain unchanged even though the US Inflation Reduction Act (IRA) aims to cut pharmaceutical prices.

Since the stock’s low-point in 2025 in April, the Israeli pharmaceutical company’s share price has risen over 60%.

Hospital director Prof. Shlomi Codish now has the budget required for rehabilitating the hospital that was badly damaged by an Iranian missile.

This is the first time such approval has been received for a home ultrasound device.

Medical device giant Medtronic, which has 1,000 employees at eight development centers in Israel, is set to lay off 60 employees at its Jerusalem Oridion development center.

Despite the war and relatively low investment in the health system, Israel outperforms most developed countries in terms of life expectancy.

DigitalOwl's technology analyzes and summarizes medical records, serving insurance companies and lawyers.

The company, which was founded in Israel, has a drug for treatment of fatty liver in phase III trials, which was initially an asset of Teva.

The pre-clinical school is the brainchild of Dr. Moshe Cohen, who also sees it as a way of boosting medical services in Eilat, but it has yet to be decided who will run it.

The US Food and Drug Administration has granted clearance to Microbot Medical's Liberty endovascular robotic system.

Edwards Lifesciences acquired 52% of Vectorious at a similar valuation in 2023, and is now buying the remaining stake of the Israeli company, which develops devices to treat heart disease.

Druckenmiller's Duquesne Family office has purchased 16 million shares in the Israeli pharmaceutical company over the past year.

Rambam is testing a first of its kind genetically modified treatment for non-genetic heart failure, and is collaborating on genetically edited cholesterol-lowering drugs.

The Tel Aviv-based company develops powder-based Intranasal specialized treatments.

According to "The Wall Street Journal," the average target price of 11 investment institutions covering Teva's stock is $24.29, a 57.9% premium on the current share price.

The Israeli pharmaceutical company beat the analysts on profit but missed on revenue in the second quarter of 2025.

The Israeli company has developed an AI platform for supporting medical decisions.

Menora Mivtachim and Phoenix have become parties in interest in the Israeli pharmaceutical company.

The company says it is making structural adjustments, mainly in the development department.

The company's revenue is growing, but it is yet to post a profit. CEO Maurice Ferré: The market no longer tolerates losses.

Haifa University researchers have found that synchronization between organs declines with age, opening up new possibilities for diagnostics, and perhaps even intervention.

The company's transcatheter approach introduces a new minimally invasive therapeutic option for heart failure patients who have limited effective treatments today.

The Israeli company is developing AI-based personalized medicines in collaboration with Oracle.

Challenges will be announced twice a year for startups to offer technological solutions for Teva's entire drug development chain.

Besides its regular donors, the institute is asking the general public to help restore facilities hit by an Iranian missile. Ben Gurion University has embarked on a similar campaign.

The company has developed the ORYOM robotic surgery platform for cataract and other eye diseases.

The company has emerged from stealth and announced that it has raised $3.6 million in a pre-seed financing round.

The Israeli company's treatment is a delayed-release antibiotic administered in the area where the patient has undergone surgery.

Investors highlighted challenges and strategic models in life sciences funding, in a forum co-hosted by Lipa Meir & Co.